Quantcast

Latest Coagulation Stories

2014-07-17 23:04:20

Zoll, Kranz & Borgess, LLC, (ZKB), an experienced pharmaceutical and medical device litigation firm, is currently investigating claims of individuals who developed bleeding, clotting or other serious side effects or even death after taking the pharmaceutical drug, Xarelto® (rivaroxaban). Toledo, OH (PRWEB) July 17, 2014 Xarelto® (rivaroxaban) is an anticoagulant marketed in the U.S. by Janssen Pharmaceutical, a subsidiary of Johnson & Johnson. It is used to prevent blood...

2014-07-16 08:27:31

SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these clinical studies is to evaluate the potential of fostamatinib to increase the platelet counts of patients with chronic ITP. Fostamatinib may provide a novel therapeutic for the underlying cause of this...

2014-07-07 16:23:47

First Recombinant Treatment Approved in US for Patients With GT With Refractoriness to Platelet Transfusions, With or Without Antibodies to Platelets PLAINSBORO, N.J., July 7, 2014 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved NovoSeven(®) RT (Coagulation Factor VIIa [Recombinant]) as the first recombinant treatment for bleeding episodes and perioperative management in patients with Glanzmann's Thrombasthenia (GT) with refractoriness to...

2014-06-11 08:32:01

LONDON, June 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Coagulation Diagnostic Testing Marketshttp://www.reportbuyer.com/pharma_healthcare/diagnostics/coagulation_diagnostic_testing_markets_1.html Coagulation testing, which encompasses both laboratory and point of care (POC) testing, will continue to be one of the most important segments of the in vitro diagnostics market for the foreseeable future. Many of the new models of laboratory...

2014-06-10 23:02:32

Transparency Market Research added a new report "Hemophilia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/hemophilia-treatment-market.html. Albany, New York (PRWEB) June 10, 2014 Hemophilia is a group of hereditary genetic disorders that affects the body’s ability to control blood coagulation. The bleeding can be internal or external,...

2014-05-22 08:28:45

Seven-fold lower incidence of VTEs in patients treated with ISIS-FXIRx compared to enoxaparin CARLSBAD, Calif., May 22, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive top-line data from a Phase 2 comparator-controlled study evaluating the incidence of venous thrombolic events (VTE) in patients treated with ISIS-FXI(Rx) undergoing total knee replacement surgery, or total knee arthroplasty (TKA). ISIS-FXI(Rx) inhibits the production of Factor...

2014-05-12 08:31:01

- Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A WHIPPANY, N.J., May 12, 2014 /PRNewswire/ -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults...

2014-05-11 20:21:16

Data showing improved pharmacokinetic profile to be presented at World Federation of Hemophilia Congress MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and III findings presented today by CSL Behring at the World Federation of Hemophilia (WFH) 2014 Congress demonstrate an improved pharmacokinetic (PK) profile of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) among hemophilia B patients of all age groups. These...

2014-05-05 20:26:32

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024http://www.reportbuyer.com/pharma_healthcare/diseases/bleeding_disorders_world_pharmaceutical_industry_market_2014_2024.htmlReport DetailsTreating abnormal bleeding - this new report shows you trends, R&D outlooks, and sales forecastsTreatments for bleeding - what're their prospects? Visiongain's new report gives you...

2014-05-02 08:25:41

KING OF PRUSSIA, Pa., May 2, 2014 /PRNewswire/ -- CSL Behring today announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the efficacy, safety and pharmacokinetics of its novel investigational recombinant factor VIII single chain (rVIII-SingleChain) for the treatment of previously treated children (up to age 11 years) with severe hemophilia A. The study site for this first enrollment is Malaysia. A minimum of 25 previously treated...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related